Eli Lilly and Company (India) Pvt. Ltd. and Cipla Ltd. have entered into a strategic agreement for the distribution and promotion of tirzepatide in India under the brand name Yurpeak®.
Under the pact, Cipla will distribute and promote Yurpeak®, expanding the availability of the diabetes and obesity treatment beyond cities where Lilly already operates. Lilly will continue manufacturing and supplying the drug at the same price as its existing brand, Mounjaro®.
Lilly India President and GM Winselow Tucker said the collaboration reinforces the company’s commitment to expanding access to innovative treatments for chronic diseases such as type 2 diabetes and obesity.
Cipla’s Global COO Achin Gupta said the partnership marks the company’s entry into obesity care, aligning with its goal of enhancing patient access to advanced global therapies.
Yurpeak® (tirzepatide) is a dual GIP and GLP-1 receptor agonist, prescribed as an adjunct to diet and exercise for managing type 2 diabetes and chronic weight conditions. It will be available in KwikPen® prefilled pens in six dose strengths (2.5 mg to 15 mg), allowing tailored treatment plans.
India has nearly 101 million people with diabetes and about 100 million adults affected by obesity, making improved access to treatments like tirzepatide crucial for better health outcomes.